Intravenous thrombolysis in stroke patients taking novel oral anticoagulants: experience with the low-dose 0.6 mg/kg of recombinant tissue-type plasminogen activator. Case reports
- 7 July 2018
- journal article
- letter
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 393, 24-26
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic StrokeNew England Journal of Medicine, 2016
- Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assaysThrombosis Journal, 2014
- Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trialsThe Lancet, 2014
- Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with RivaroxabanJournal of Stroke and Cerebrovascular Diseases, 2014
- Management of Acute Stroke in Patients Taking Novel Oral AnticoagulantsInternational Journal of Stroke, 2014
- Guidelines for the Early Management of Patients With Acute Ischemic StrokeStroke, 2013
- Efficacy and Safety of the Novel Oral Anticoagulants in Atrial FibrillationCirculation, 2012
- Using Dabigatran in Patients With StrokeStroke, 2012
- Newer Oral Anticoagulants Should Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation and Risk Factors for Stroke or ThromboembolismCirculation, 2012
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995